DRUG

hydroxychloroquine

12 hypotheses across 5 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

hydroxychloroquine appears in hypotheses across 5 disease domains: Epilepsy, Glioblastoma, Inflammatory bowel disease, Pancreatic cancer, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: STAT3.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for hydroxychloroquine

Epilepsy 1

Mediator Outcome Score Tier Lit. status Trial
STAT3 general cell loss 0.208 Mid novel signal none

Glioblastoma 1

Mediator Outcome Score Tier Lit. status Trial
STAT3 glioblastoma progression 0.208 Mid novel signal active

Inflammatory bowel disease 4

Mediator Outcome Score Tier Lit. status Trial
myeloperoxidase NASH 0.312 High partial evidence active
myeloperoxidase fibrosis 0.312 High reproduces known completed
myeloperoxidase tissue damage 0.312 High reproduces known active
myeloperoxidase hepatic inflammation 0.312 High novel signal none

Pancreatic cancer 4

Mediator Outcome Score Tier Lit. status Trial
STAT3 drug resistance 0.208 Mid reproduces known none
STAT3 pancreatic cancer 0.208 Mid reproduces known active
STAT3 pancreatic ductal adenocarcinoma 0.208 Mid reproduces known active
STAT3 immune escape 0.208 Mid partial evidence none

Rheumatoid arthritis 2

Mediator Outcome Score Tier Lit. status Trial
STAT3 prurigo nodularis 0.312 High novel signal none
STAT3 arthritis 0.208 Mid reproduces known active

Clinical trials

200 registered trials for hydroxychloroquine

Source: ClinicalTrials.gov